Similar articles

• Industry continues dabbling with open innovation models.

  Sheridan C. Sheridan C. Nat Biotechnol. 2011 Dec 8;29(12):1063-5. doi: 10.1038/nbt1211-1063a. Nat Biotechnol. 2011. PMID: 22158347 No abstract available.
• Strategic emphases for tropical diseases research: a TDR perspective.

  Remme JH, Blas E, Chitsulo L, Desjeux PM, Engers HD, Kanyok TP, Kayondo JF, Kioy DW, Kumaraswami V, Lazdins JK, Nunn PP, Oduola A, Ridley RG, Toure YT, Zicker F, Morel CM. Remme JH, et al. Trends Microbiol. 2002 Oct;10(10):435-40. doi: 10.1016/s0966-842x(02)02431-9. Trends Microbiol. 2002. PMID: 12377547
• Global framework on essential health R&D.

  Chirac P, Torreele E. Chirac P, et al. Lancet. 2006 May 13;367(9522):1560-1. doi: 10.1016/S0140-6736(06)68672-8. Lancet. 2006. PMID: 16698397 No abstract available.
• WIPO Re:Search: a consortium catalyzing research and product development for neglected tropical diseases.

  Dent J, Ramamoorthi R, Graef K, Nelson LM, Wichard JC. Dent J, et al. Pharm Pat Anal. 2013 Sep;2(5):591-6. doi: 10.4155/ppa.13.49. Pharm Pat Anal. 2013. PMID: 24237166 Review. No abstract available.
• Programmes, partnerships, and governance for elimination and control of neglected tropical diseases.

  Liese B, Rosenberg M, Schratz A. Liese B, et al. Lancet. 2010 Jan 2;375(9708):67-76. doi: 10.1016/S0140-6736(09)61749-9. Lancet. 2010. PMID: 20109865 Review.